tetano
Editor, Senior Moderator
Intern Emerg Med
. 2022 Feb 9.
doi: 10.1007/s11739-022-02933-x. Online ahead of print.
NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study
Paulina Moctezuma-Velázquez[SUP] 1 [/SUP], Godolfino Miranda-Zazueta[SUP] 1 [/SUP], Edgar Ortiz-Brizuela[SUP] 2 [/SUP], Juan Alberto Garay-Mora[SUP] 3 [/SUP], María Fernanda González-Lara[SUP] 2 [/SUP], Karla Maria Tamez-Torres[SUP] 2 [/SUP], Carla Marina Román-Montes[SUP] 2 [/SUP], Bruno Alejandro Díaz-Mejía[SUP] 4 [/SUP], Esteban Pérez-García[SUP] 2 [/SUP], Marco Villanueva-Reza[SUP] 2 [/SUP], Monica Chapa-Ibargüengoitia[SUP] 3 [/SUP], Luis Uscanga-Domínguez[SUP] 5 [/SUP], José Sifuentes-Osornio[SUP] 4 [/SUP], Alfredo Ponce-de-León[SUP] 2 [/SUP], David Kershenobich-Stalnikowitz[SUP] 5 [/SUP], Blanca Mota-Ayala[SUP] 5 [/SUP], Carlos Moctezuma-Velázquez[SUP] 6 7 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 is a worldwide health challenge. Liver steatosis diagnosis based on imaging studies has been implicated in poor outcomes of COVID-19 pneumonia, but results are inconsistent. The Dallas Steatosis Index (DSI) is an available calculator developed to identify patients with non-alcoholic fatty liver disease (NAFLD). We hypothesized that it would be associated with in-hospital mortality, intensive care unit admission (ICU), and invasive mechanical ventilation (IMV). We conducted a retrospective cohort study on inpatients with confirmed COVID-19 pneumonia between February 26 and April 11, 2020. We computed the DSI on admission, and patients with high DSI were considered with NAFLD. We employed logistic regression to study the association between NAFLD, mortality, ICU admission, and IMV. We studied the association between liver steatosis on computed tomography (CT) and these outcomes, and also between Metabolic Associated Fatty Liver Disease (MAFLD) based on CT findings and risk factors and the outcomes. 470 patients were included; 359 had NAFLD according to the DSI. They had a higher frequency of type 2 diabetes (31% vs 14%, p < 0.001), obesity (58% vs 14%, p < 0.001), and arterial hypertension (34% vs 22%, p = 0.02). In univariable analysis, NAFLD was associated with mortality, ICU admission, and IMV. Liver steatosis by CT and MAFLD were not associated with any of these outcomes. In multivariable logistic regression, high DSI remained significantly associated with IMV and death. High DSI, which can be easily computed on admission, was associated with IMV and death, and its use to better stratify the prognosis of these patients should be explored. On the other hand, liver steatosis by CT and MAFLD were not associated with poor outcomes.
Keywords: COVID-19; Coronavirus; Fatty liver disease; Liver steatosis; NAFLD.
. 2022 Feb 9.
doi: 10.1007/s11739-022-02933-x. Online ahead of print.
NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study
Paulina Moctezuma-Velázquez[SUP] 1 [/SUP], Godolfino Miranda-Zazueta[SUP] 1 [/SUP], Edgar Ortiz-Brizuela[SUP] 2 [/SUP], Juan Alberto Garay-Mora[SUP] 3 [/SUP], María Fernanda González-Lara[SUP] 2 [/SUP], Karla Maria Tamez-Torres[SUP] 2 [/SUP], Carla Marina Román-Montes[SUP] 2 [/SUP], Bruno Alejandro Díaz-Mejía[SUP] 4 [/SUP], Esteban Pérez-García[SUP] 2 [/SUP], Marco Villanueva-Reza[SUP] 2 [/SUP], Monica Chapa-Ibargüengoitia[SUP] 3 [/SUP], Luis Uscanga-Domínguez[SUP] 5 [/SUP], José Sifuentes-Osornio[SUP] 4 [/SUP], Alfredo Ponce-de-León[SUP] 2 [/SUP], David Kershenobich-Stalnikowitz[SUP] 5 [/SUP], Blanca Mota-Ayala[SUP] 5 [/SUP], Carlos Moctezuma-Velázquez[SUP] 6 7 [/SUP]
Affiliations
- PMID: 35138548
- DOI: 10.1007/s11739-022-02933-x
Abstract
Coronavirus disease 2019 is a worldwide health challenge. Liver steatosis diagnosis based on imaging studies has been implicated in poor outcomes of COVID-19 pneumonia, but results are inconsistent. The Dallas Steatosis Index (DSI) is an available calculator developed to identify patients with non-alcoholic fatty liver disease (NAFLD). We hypothesized that it would be associated with in-hospital mortality, intensive care unit admission (ICU), and invasive mechanical ventilation (IMV). We conducted a retrospective cohort study on inpatients with confirmed COVID-19 pneumonia between February 26 and April 11, 2020. We computed the DSI on admission, and patients with high DSI were considered with NAFLD. We employed logistic regression to study the association between NAFLD, mortality, ICU admission, and IMV. We studied the association between liver steatosis on computed tomography (CT) and these outcomes, and also between Metabolic Associated Fatty Liver Disease (MAFLD) based on CT findings and risk factors and the outcomes. 470 patients were included; 359 had NAFLD according to the DSI. They had a higher frequency of type 2 diabetes (31% vs 14%, p < 0.001), obesity (58% vs 14%, p < 0.001), and arterial hypertension (34% vs 22%, p = 0.02). In univariable analysis, NAFLD was associated with mortality, ICU admission, and IMV. Liver steatosis by CT and MAFLD were not associated with any of these outcomes. In multivariable logistic regression, high DSI remained significantly associated with IMV and death. High DSI, which can be easily computed on admission, was associated with IMV and death, and its use to better stratify the prognosis of these patients should be explored. On the other hand, liver steatosis by CT and MAFLD were not associated with poor outcomes.
Keywords: COVID-19; Coronavirus; Fatty liver disease; Liver steatosis; NAFLD.